Skip to main content
. 2022 Aug 6;10(5):2125–2136. doi: 10.1016/j.gendis.2022.06.010

Figure 5.

Fig. 5

SKP2 knockdown alleviated the promotion of osteosarcoma from CHPF overexpression. (A) MTT assay was performed to examine the effects of CHPF overexpression, SKP2 downregulation as well as CHPF overexpression combining with SKP2 downregulation on MNNG/HOS cell proliferation. (B) Flow cytometry was performed to detect the effects of CHPF overexpression, SKP2 downregulation as well as CHPF overexpression combining with SKP2 downregulation on MNNG/HOS cell apoptosis. (C, D) The effects of CHPF overexpression, SKP2 downregulation as well as CHPF overexpression combining with SKP2 downregulation on MNNG/HOS cell migration were evaluated by Transwell (C) and wound healing (D) assays. (E) The expression of some well-known cancer-associated elements was detected by Western blotting in MNNG/HOS cells after silencing CHPF. (F) Western blotting revealed protein expression of AKT, p-AKT, mTOR and p-mTOR in shCtrl or shCHPF infected MNNG/HOS cells treated with or without an AKT activator: SC79. (G) Flow cytometry experiment showed the changes in shCtrl or shCHPF infected MNNG/HOS cell apoptosis after treatment with or without SC79. The data were expressed as mean ± SD (n ≥ 3). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.